Table 5.
Metastasis | Cancer-specific mortality | ||||||||
---|---|---|---|---|---|---|---|---|---|
Tested very-high-risk definitions | H.R. | p | 95% C.I. | c-index | H.R. | p | 95% C.I. | c-index | Very high risk sample size |
CAPRA ≥4 | 2.81 | 0.305 | 0.39, 20.3 | 0.6100 | 1.12 | 0.913 | 0.15, 8.23 | 0.6599 | 540 (95.4%) |
CAPRA ≥5 | 3.08 | 0.009 | 1.32, 7.18 | 0.6531 | 1.01 | 0.980 | 0.41, 2.49 | 0.6592 | 405 (71.6%) |
CAPRA ≥6 | 2.48 | 0.001 | 1.47, 4.20 | 0.6487 | 1.40 | 0.351 | 0.69, 2.82 | 0.6553 | 231 (40.8%) |
CAPRA ≥7 | 2.27 | 0.003 | 1.33, 3.87 | 0.6538 | 1.77 | 0.135 | 0.84, 3.73 | 0.6676 | 99 (17.5%) |
CAPRA ≥8 | 1.65 | 0.220 | 0.74, 3.67 | 0.6161 | 2.00 | 0.134 | 0.81, 4.94 | 0.6560 | 34 (6.0%) |
Primary pattern 5 or ≥5 cores with sum 8–10 or multiple high-risk features | 2.26 | 0.005 | 1.28, 4.00 | 0.6413 | 2.35 | 0.031 | 1.08, 5.12 | 0.6874 | 93 (16.4%) |